Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Sep;60(8):1632-1643.
doi: 10.1111/head.13889. Epub 2020 Jun 25.

Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster Headache

Joan Crespi  1   2 , Daniel Bratbak  2   3 , David W Dodick  2   4 , Manjit Matharu  5 , Ole Solheim  2   3 , Sasha Gulati  2   3 , Erik Magnus Berntsen  6   7 , Erling Tronvik  1   2
Affiliations
Clinical Trial

Open-Label, Multi-Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster Headache

Joan Crespi et al. Headache. 2020 Sep.

Abstract

Background: The otic ganglion (OG) provides parasympathetic innervation to the cerebral circulation and cranial structures and may be involved in the pathophysiology of trigeminal autonomic headaches. This structure has never been targeted in any headache disorder.

Objective: To investigate the safety of injecting onabotulinumtoxin A (BTA) toward the OG in 10 patients with intractable chronic cluster headache and to collect efficacy data.

Methods: A total of 10 patients with chronic cluster headache were enrolled in this open-label, multi-dose pilot safety study. All patients were recruited and treated on an out-patient basis at St Olav's University Hospital (Norway). In 5 patients each, the OG was the injection target with 12.5 IU of BTA or 25 IU, respectively. The primary outcome measure was adverse events (AEs) and the main secondary outcome was the number of attacks per week measured at baseline and in the second month following injection.

Results: For the primary endpoint, we analyzed data for all 10 patients. There were a total of 17 AEs in 6 of the 10 patients. All AEs were considered mild and disappeared by the end of follow-up. The median number of attacks per week at baseline was 17.0 [7.8 to 25.8] vs 14.0 [7.3 to 20.0] in the second month following injection; difference: 3 (95%CI: -0.3 to 7.9), P = .063.

Conclusions: Injection with BTA toward the OG appears to be safe. We did not find a statistically significant reduction in the number of attacks per week at month 2 after injection compared to the baseline. This study suggests that the OG is not an important target for the treatment of chronic cluster headache. A future study employing more precise targeting of the OG may be indicated.

Keywords: botulinum toxin; chronic cluster headache; otic ganglion; pterygopalatine ganglion; sphenopalatine ganglion; trigeminal autonomic cephalalgia.

PubMed Disclaimer

References

    1. Crespi J, Bratbak D, Dodick DW, et al. Anatomical landmarks for localizing the otic ganglion: A possible new treatment target for headache disorders. Cephalalgia Rep. 2019;2:1-7.
    1. Fischera M, Marziniak M, Gralow I, Evers S. The incidence and prevalence of cluster headache: A meta-analysis of population-based studies. Cephalalgia. 2008;28:614-618.
    1. Leone M, Cecchini AP, Mea E, Tullo V, Bussone G. Epidemiology of fixed unilateral headaches. Cephalalgia. 2008;28(Suppl. 1):8-11.
    1. Jensen RM, Lyngberg A, Jensen RH. Burden of cluster headache. Cephalalgia. 2007;27:535-541.
    1. Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Oxygen inhibits neuronal activation in the trigeminocervical complex after stimulation of trigeminal autonomic reflex, but not during direct dural activation of trigeminal afferents. Headache. 2009;49:1131-1143.

Publication types

MeSH terms